(NASDAQ: MRVI) Maravai Lifesciences Holdings's forecast annual revenue growth rate of -3.52% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 130.42%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.85%.
Maravai Lifesciences Holdings's revenue in 2025 is $241,856,000.On average, 5 Wall Street analysts forecast MRVI's revenue for 2025 to be $49,937,457,986, with the lowest MRVI revenue forecast at $47,986,766,086, and the highest MRVI revenue forecast at $52,205,200,985. On average, 5 Wall Street analysts forecast MRVI's revenue for 2026 to be $55,478,594,417, with the lowest MRVI revenue forecast at $53,351,168,812, and the highest MRVI revenue forecast at $59,633,619,096.
In 2027, MRVI is forecast to generate $67,956,910,750 in revenue, with the lowest revenue forecast at $61,948,474,105 and the highest revenue forecast at $73,965,347,394.